Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VisgeneerROCO:4197 +9.22%54 Gross Margin % is 27.46% as of Dec. 2025, which is 30% below its 10-year median of 39.45. GuruFocus rates ROCO:4197 with a GF Score™ of 54/100 and a GF Value™ of NT$13.79 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Visgeneer ranks worse than 70.36% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Visgeneer's Gross Profit for the
six
months ended in Dec. 2025 was NT$24.5 Mil. Visgeneer's Revenue for the
six
months ended in Dec. 2025 was NT$89.1 Mil. Therefore, Visgeneer's Gross Margin % for the quarter that ended in Dec. 2025 was 27.46%.
The historical rank and industry rank for Visgeneer's Gross Margin % or its related term are showing as below:
ROCO:4197'
s Gross Margin % Range Over the Past 10 Years
Min: 24.63 Med: 39.45 Max: 46.01
Current: 38.2
During the past 13 years, the highestGross Margin % of Visgeneer was 46.01%. The lowest was 24.63%. And the median was 39.45%.
ROCO:4197's Gross Margin % is ranked worse than 70.36% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:4197: 38.20
Visgeneer had a gross margin of 27.46% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Visgeneer was 2.40% per year.
Visgeneer (ROCO:4197) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Visgeneer had a gross margin of 27.46% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Visgeneer Gross Margin % Related Terms
Visgeneer Gross Margin % Historical Data
* Premium members only.
The historical data trend for Visgeneer's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4197 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Visgeneer's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Visgeneer Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Visgeneer's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Visgeneer's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Visgeneer (ROCO:4197) has a Gross Margin % of 27.46% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Visgeneer and its competitors. This is 30% below median its historical median of 39.45. Over the past decade, Visgeneer's Gross Margin % has ranged from 24.63 to 46.01. According to the industry distribution chart, Visgeneer ranks #515 out of 732 companies in the Biotechnology industry, placing it in the top 70.4%.
Is Visgeneer's Gross Margin % too high?
Visgeneer's current Gross Margin % of 27.46% is 30% below median its 10-year median of 39.45. Over the past 10 years, this metric has ranged from a low of 24.63 to a high of 46.01. The Biotechnology industry median Gross Margin % is 60.91. Visgeneer's value of 27.46% is 54.9% below this industry median. Based on the distribution chart, Visgeneer ranks #515 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Visgeneer has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Visgeneer's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Visgeneer ranks #515 out of 732 companies for Gross Margin %. This places Visgeneer in the lower half of its industry. The industry median Gross Margin % is 60.91. Visgeneer's value of 27.46% is 54.9% below this benchmark. Historically, Visgeneer's own Gross Margin % has ranged from 24.63 to 46.01 over the past decade. While the company's 10-year median is 39.45 vs. the industry median of 60.91, Visgeneer has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Visgeneer's current Gross Margin % of 27.46% is 54.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Visgeneer and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Visgeneer's current Gross Margin % is 27.46%, which is 30% below median its own 10-year median of 39.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Visgeneer stock overvalued right now?
Based on GuruFocus' analysis, Visgeneer (ROCO:4197) is currently considered Possible Value Trap. The stock's GF Value™ is NT$13.79, compared to a current price of NT$9.48 — trading 31.3% below its estimated fair value. The current Gross Margin % is 27.46%, which is 30% below median its 10-year median of 39.45 and 54.9% below the Biotechnology industry median of 60.91. Visgeneer's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Visgeneer (ROCO:4197), the current Gross Margin % is 27.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Visgeneer (ROCO:4197) Overvalued in 2026?
Based on GuruFocus' analysis, Visgeneer stock appears to be undervalued.
The current stock price of NT$9.48 is trading 31.3% below its estimated GF Value™ of NT$13.79.
GuruFocus considers Visgeneer to be Possible Value Trap.
Key valuation signals for ROCO:4197:
Gross Margin %: 27.46% (30% below median its 10-year median of 39.45)
GF Value™: NT$13.79 vs. price of NT$9.48 (31.3% below fair value)
Industry Position: 54.9% below the Biotechnology median (#515 of 732)
No single metric tells the full story. See the ROCO:4197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Visgeneer Inc is a Taiwan based Biotech company involved in developing and, manufacturing biomedical products in the areas of Bacterial Fermentation, Medical Device, Cosmetics/Skin Care, and Cancer Gene identification. Its products include Blood Glucose and Ketone Monitoring System, Ginkgo Biloba series, Peptide-Complex series, Hyaluronic Acid Essence Series and High-Quality Masks among others.
54GF Score
Get the complete analysis for ROCO:4197
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4197 has been successfully added to your 
